A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicenter, open-label, first-in-human (FIH) study designed to evaluate
the safety, tolerability, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD)
of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or
metastatic solid tumors with RAS or RAF mutations. The study consists of 2 parts, a
dose-escalation phase, and an expansion phase.